ASXL1 and myelodysplastic syndrome: Among 161 TP53-mutated patients (10.1% of 1589 MDS cases), we identified a predominance of missense mutations (76.9%) and frequent co-occurrence with epigenetic modifiers, notably DNMT3A (11.8%), TET2 (10.6%), and ASXL1 (9.3%).